Pharma Tech

Celltrion and Kaigene sign $580m licence deal for KG013

Oct 23, 2026, 8:46 AM

Read Full Article → Celltrion and Kaigene sign $580m licence deal for KG013

Translate article text

Choose a language and wait for the translated text.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.